# Neutrophil-initiated nociceptive ingrowth orchestrates inflammation resolution to potentiate bone regeneration

**Authors:** Xuanyu Qi, Guangzheng Yang, Zeqian Xu, Mingliang Zhou, Tejing Liu, Jiahui Du, Sihan Lin, Xinquan Jiang

PMC · DOI: 10.1038/s41413-025-00481-6 · Bone Research · 2026-01-19

## TL;DR

Nociceptive nerves help resolve inflammation during bone healing by working with neutrophils and osteoblasts, offering new treatment ideas for inflammatory bone diseases.

## Contribution

Discovery of a neuroimmune feedback loop involving neutrophils, nociceptors, and osteoblasts that regulates inflammation resolution during bone regeneration.

## Key findings

- Neutrophils trigger nociceptive ingrowth that suppresses inflammation via LXA4 production in osteoblasts.
- Nociceptor-derived CGRP activates osteoblastic autophagy to promote LXA4 biosynthesis.
- Reduced nociceptive innervation in diabetic patients correlates with impaired bone healing and increased inflammation.

## Abstract

Nociceptive pain is a cardinal feature of traumatic and inflammatory bone diseases. However, whether and how nociceptors actively regulate the immune response during bone regeneration remains unclear. Here, we found that neutrophil-triggered nociceptive ingrowth functioned as negative feedback regulation to inflammation during bone healing. A unique Il4ra+Ccl2high neutrophil subset drove intense postinjury TRPV1+ nociceptive ingrowth, which in return dissipated inflammation by activating the production of pro-resolving mediator lipoxin A4 (LXA4) in osteoblasts. Mechanistically, osteoblastic autophagy activated by nociceptor-derived calcitonin gene-related peptide (CGRP) suppressed the nuclear translocation of arachidonate 5-lipoxygenase (5-LOX) to favor the LXA4 biosynthesis. Moreover, in alveolar bone from patients with Type II diabetes, we found diminished nociceptive innervation correlated with reduced autophagy, increased inflammation, and impaired bone formation. Activating nociceptive nerves by spicy diet or topical administration of a clinical-approved TRPV1 agonist showed therapeutic benefits on alveolar bone healing in diabetic mice. These results reveal a critical neuroimmune interaction underlying the inflammation-regeneration balance during bone repairing and may lead to novel therapeutic strategies for inflammatory bone diseases.

## Linked entities

- **Genes:** TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442], IL4R (interleukin 4 receptor) [NCBI Gene 3566], CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347], CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796], ALOX5 (arachidonate 5-lipoxygenase) [NCBI Gene 240]
- **Chemicals:** lipoxin A4 (PubChem CID 3934)
- **Diseases:** Type II diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}, TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442] {aka VR1}, ALOX5 (arachidonate 5-lipoxygenase) [NCBI Gene 240] {aka 5-LO, 5-LOX, 5LPG, LOG5}, IL4R (interleukin 4 receptor) [NCBI Gene 3566] {aka CD124, IL-4RA, IL4RA}
- **Diseases:** inflammation (MESH:D007249), pain (MESH:D010146), diabetic (MESH:D003920), inflammatory bone diseases (MESH:D001847), Type II diabetes (MESH:D003924)
- **Chemicals:** LXA4 (MESH:C040527)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12816638/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12816638/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12816638/full.md

---
Source: https://tomesphere.com/paper/PMC12816638